2018 Bio International Convention | Lynda Graham, MBA
Let’s meet at Bio!
Learn about the FDA & EMA Pediatric Guidelines that may impact your Drug Development Process.
Our seasoned team brings expertise and insight to pharmaceutical companies of all sizes to effectively navigate the complex pediatric regulatory environments in the US and Europe. Our “Pediatric Center of Excellence” model is a unique resource of pediatricians, pharmacometricians, regulatory, drug safety and formulation scientists that develop pediatric drugs through all stages of development. By working with KinderPharm our clients benefit by advancing medicines for pediatric patients in a more efficient and cost-effective manner.
BIO is a great opportunity to meet with the experts at KinderPharm. Our employees are among the best in their fields, offering expertise across all aspects of pediatric drug development.
Visit us at Booth #2431 or schedule a one-on-one meeting with an expert today by clicking here!
Dr. Martin A Graham is a graduate of Leeds University, England where he earned his BSc in Pharmacology and Microbiology with Joint Honors in 1984. He went on to earn his PhD from the University of London at The Institute of Cancer Research, Royal Marsden Hospital, London UK in 1990. Dr. Graham conducted his post-doctoral research in anti-cancer drug development at the Beatson Institute at University of Glasgow before joining Sterling-Winthrop Pharmaceuticals, which later became Sanofi-Synthelabo, in both the UK and the US. Dr. Graham later served as Director of Pharmacokinetics at Centocor Corporation, a Johnson and Johnson Company; VP of Research and Development at Gemin X biotechnologies; and VP of Development and Regulatory Affairs at TetraLogic Pharmaceuticals.
Dr. Graham founded PKPD Bioscience in 2004 where he currently serves is President and CEO. A decade later he founded KinderPharm in 2014, a pediatric drug development company where Dr. Graham also serves as President and CEO. With his extensive R&D experience with both small molecules and protein therapeutics from IND to NDA/BLA, Dr. Graham has been involved in numerous regulatory filings in the U.S., Japan and Europe for a wide variety of products including Oxaliplatin, Rasburicase, Mitoguazone, Tirapazamine, Alfuzosin, Birinapant, Stelara and Remicade.
Dr. Graham is an Honorary Professor of Pharmacokinetics and Pharmacodynamics at the University of Bradford, Yorkshire, UK and is a specialist in PK/PD modeling clinical trial simulation. He is the author of a text book on the Pharmacokinetics of Cancer Chemotherapy and has substantial publication record in the area of pharmacokinetics, drug metabolism and clinical pharmacology.